Stock AnalizOrganon & Co. OGN
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Organon & Co. (OGN) is a healthcare company listed in the US with a market value of about $3.7B. In the twelve months to September 30, 2026 it had revenue of $6.1B and net income of $213M, a net margin of 3.5%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (1/5).
Key numbers: a P/E of 18.1, a price to free cash flow of 5.4, 5-year revenue growth of -1% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1B | $6.2B | $6.4B | $6.3B | $6.2B | $6.3B | $6.5B | $7.8B |
| Net income | $213M | $187M | $864M | $1.0B | $917M | $1.4B | $2.2B | $3.2B |
| Free cash flow | $675M | $538M | $764M | $548M | $662M | $2.0B | $2.0B | $2.9B |
| EPS (diluted) | $0.77 | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 | $8.52 | $12.69 |
| Net margin | 3.5% | 3.0% | 13.5% | 16.3% | 14.8% | 21.4% | 33.1% | 41.4% |
| ROIC | — | 7.7% | 11.0% | 10.7% | 15.3% | 20.1% | 40.9% | 47.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $10.33, 26% below the current price; targets range from $8.00 to $14.00; the consensus rating is “Hold”; expected EPS is $3.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Organon &’s P/E ratio?
About 18.1, based on the last twelve months of diluted earnings per share (forward P/E about 3.8).
Is Organon & stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Organon & pay a dividend?
Yes. The dividend yield is about 0.58%, and it has paid dividends for 5 years in our data.
Is Organon & a good stock to buy?
We do not give buy or sell advice. Organon & scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.